On the public citation graph
Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience
0 signed · 350 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2020.10044openalex-snapshot
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
inferredcites →https://doi.org/10.1001/jama.2020.13319openalex-snapshot
Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments
inferredcites →https://doi.org/10.1016/j.ajpath.2020.05.014openalex-snapshot
Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma
inferredcites →https://doi.org/10.1016/j.jbi.2008.08.010openalex-snapshot
Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
inferredcites →https://doi.org/10.1016/j.jbi.2019.103208openalex-snapshot
The REDCap consortium: Building an international community of software platform partners
inferredcites →https://doi.org/10.1016/j.mayocp.2021.02.008openalex-snapshot
The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis
inferredcites →https://doi.org/10.1084/jem.17.5.553openalex-snapshot
THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS
inferredcites →https://doi.org/10.1093/clinids/21.1.150openalex-snapshot
Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases
inferredcites →https://doi.org/10.1097/ccm.0b013e3181d44c1eopenalex-snapshot
Hark back: Passive immunotherapy for influenza and other serious infections
inferredcites →https://doi.org/10.1128/aac.38.8.1695openalex-snapshot
Serum therapy revisited: animal models of infection and development of passive antibody therapy
inferredcites →https://doi.org/10.1128/jcm.01243-20openalex-snapshot
Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2
inferredcites →https://doi.org/10.1172/jci138745openalex-snapshot
Deployment of convalescent plasma for the prevention and treatment of COVID-19
inferredcites →https://doi.org/10.1172/jci140200openalex-snapshot
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
inferredcites →https://doi.org/10.7326/0003-4819-145-8-200610170-00139openalex-snapshot
Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1001/jamaoncol.2021.1799openalex-snapshot
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
inferred← citeshttps://doi.org/10.1002/14651858.cd013600.pub2openalex-snapshot
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review
inferred← citeshttps://doi.org/10.1002/14651858.cd013600.pub3openalex-snapshot
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review
inferred← citeshttps://doi.org/10.1002/bies.202000200openalex-snapshot
Can BCG vaccine protect against COVID‐19 via trained immunity and tolerogenesis?
inferred← citeshttps://doi.org/10.1002/ccr3.3964openalex-snapshot
Combination of convalescent plasma therapy and repurposed drugs to treat severe COVID‐19 patient with multimorbidity
inferred← citeshttps://doi.org/10.1002/cncr.33201openalex-snapshot
Mining the past to treat the present, ever mindful of the future: Low‐dose radiotherapy and COVID‐19 pneumonia
inferred← citeshttps://doi.org/10.1002/cpt.2253openalex-snapshot
When Can We Rely on Real‐World Evidence to Evaluate New Medical Treatments?
inferred← citeshttps://doi.org/10.1002/cpt.2405openalex-snapshot
First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19
inferred← citeshttps://doi.org/10.1002/cti2.1285openalex-snapshot
Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors
inferred← citeshttps://doi.org/10.1002/ctm2.571openalex-snapshot
The concentrated antibody from convalescent plasma balanced the dysfunctional immune responses in patients with critical COVID‐19
inferred← citeshttps://doi.org/10.1002/jca.21888openalex-snapshot
A matched cohort study of convalescent plasma therapy for COVID ‐19
inferred← citeshttps://doi.org/10.1002/jca.22011openalex-snapshot
Therapeutic plasma exchange: A potential therapeutic modality for critically ill adults with severe acute respiratory syndrome coronavirus 2 infection
inferred← citeshttps://doi.org/10.1002/jcph.1749openalex-snapshot
Empiric Therapeutic Anticoagulation and Mortality in Critically Ill Patients With Respiratory Failure From SARS‐CoV‐2: A Retrospective Cohort Study
inferred← citeshttps://doi.org/10.1002/jev2.12004openalex-snapshot
COVID‐19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?
inferred← citeshttps://doi.org/10.1002/jmv.26610openalex-snapshot
Pathogenesis‐directed therapy of 2019 novel coronavirus disease
inferred← citeshttps://doi.org/10.1002/rmv.2225openalex-snapshot
Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID‐19) treatment: A systematic review and meta‐analysis based on recent studies and previous respiratory pandemics
inferred← citeshttps://doi.org/10.1002/rmv.2316openalex-snapshot
Complement inhibition: A possible therapeutic approach in the fight against Covid‐19
inferred← citeshttps://doi.org/10.1007/82_2024_269openalex-snapshot
Convalescent Plasma and the US Expanded Access Program: A Personal Narrative
inferred← citeshttps://doi.org/10.1007/s11655-020-2860-xopenalex-snapshot
Chinese Medicine in Fighting against Covid-19: Role and Inspiration
inferred← citeshttps://doi.org/10.1007/s11684-023-1021-yopenalex-snapshot
Passive antibody therapy in emerging infectious diseases
inferred← citeshttps://doi.org/10.1007/s11845-022-03068-wopenalex-snapshot
Emergency myelopoiesis in critical illness: lessons from the COVID-19 pandemic
inferred← citeshttps://doi.org/10.1007/s11886-021-01551-xopenalex-snapshot
SARS-CoV-2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications
inferred← citeshttps://doi.org/10.1007/s12288-021-01417-wopenalex-snapshot
Efficacy and Safety of Convalescent Plasma for COVID-19: A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1007/s12288-025-02269-4openalex-snapshot
Prospective Evaluation of Anti-CMV Antibodies in Blood Donors: Links To Blood Group and Demographic Characteristics
inferred← citeshttps://doi.org/10.1007/s13205-020-02619-1openalex-snapshot
Recent biotechnological advances as potential intervention strategies against COVID-19
inferred← citeshttps://doi.org/10.1007/s15010-020-01557-7openalex-snapshot
Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence
inferred← citeshttps://doi.org/10.1007/s40121-020-00341-2openalex-snapshot
Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
inferred← citeshttps://doi.org/10.1007/s40121-021-00514-7openalex-snapshot
Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection
inferred← citeshttps://doi.org/10.1007/s42399-021-00827-1openalex-snapshot
The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2
inferred← citeshttps://doi.org/10.1007/s42399-021-00874-8openalex-snapshot
Repositioned Drugs for COVID-19—the Impact on Multiple Organs
inferred← citeshttps://doi.org/10.1016/b978-0-12-818619-0.00053-8openalex-snapshot
COVID-19 therapy directed against pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2
inferred← citeshttps://doi.org/10.1016/b978-0-12-824409-8.00002-3openalex-snapshot
Treatment and therapeutic agents
inferred← citeshttps://doi.org/10.1016/b978-0-323-89972-7.00011-8openalex-snapshot
Current strategies and future perspectives in COVID-19 therapy
inferred← citeshttps://doi.org/10.1016/b978-0-323-90595-4.00002-9openalex-snapshot
Lines of Treatment of COVID-19 Infection
inferred← citeshttps://doi.org/10.1016/j.addr.2021.02.009openalex-snapshot
Adaptive immune responses to SARS-CoV-2
inferred← citeshttps://doi.org/10.1016/j.ajpath.2020.10.008openalex-snapshot
Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG
inferred← citeshttps://doi.org/10.1016/j.amsu.2021.102814openalex-snapshot
Clinical features and laboratory findings first case of B. 1.617.2 (delta) variant concern (VOC) in Iraq
inferred← citeshttps://doi.org/10.1016/j.anai.2020.11.021openalex-snapshot
Zoonotic coronavirus epidemics: Severe acute respiratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019.
inferred← citeshttps://doi.org/10.1016/j.bbrc.2020.11.021openalex-snapshot
COVID19- clinical presentation and therapeutic considerations
inferred← citeshttps://doi.org/10.1016/j.bbrc.2021.08.036openalex-snapshot
Mutation-induced Changes in the Receptor-binding Interface of the SARS-CoV-2 Delta Variant B.1.617.2 and Implications for Immune Evasion
inferred← citeshttps://doi.org/10.1016/j.bcmd.2021.102548openalex-snapshot
Effectiveness of convalescent plasma in Indian patients with COVID-19
inferred← citeshttps://doi.org/10.1016/j.berh.2021.101660openalex-snapshot
Laboratory evaluation of SARS-CoV-2 in the COVID-19 pandemic
inferred← citeshttps://doi.org/10.1016/j.bios.2021.113008openalex-snapshot
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients
inferred← citeshttps://doi.org/10.1016/j.bja.2021.07.033openalex-snapshot
Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression
inferred← citeshttps://doi.org/10.1016/j.cell.2021.06.021openalex-snapshot
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
inferred← citeshttps://doi.org/10.1016/j.chom.2021.02.019openalex-snapshot
Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies
inferred← citeshttps://doi.org/10.1016/j.cjca.2021.05.009openalex-snapshot
Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently?
inferred← citeshttps://doi.org/10.1016/j.clim.2021.108849openalex-snapshot
A hitchhiker's guide through the COVID-19 galaxy
inferred← citeshttps://doi.org/10.1016/j.clinmicnews.2021.02.001openalex-snapshot
Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19
inferred← citeshttps://doi.org/10.1016/j.cll.2021.07.001openalex-snapshot
Donor Screening and Deferral
inferred← citeshttps://doi.org/10.1016/j.cpccr.2021.100057openalex-snapshot
Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients
inferred← citeshttps://doi.org/10.1016/j.drudis.2020.11.025openalex-snapshot
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
inferred← citeshttps://doi.org/10.1016/j.eclinm.2020.100545openalex-snapshot
Towards characterized convalescent plasma for COVID-19: The dose matters
inferred← citeshttps://doi.org/10.1016/j.eclinm.2021.100931openalex-snapshot
Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries
inferred← citeshttps://doi.org/10.1016/j.heliyon.2021.e08140openalex-snapshot
Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina
inferred← citeshttps://doi.org/10.1016/j.hrtlng.2020.09.003openalex-snapshot
Hospital characteristics and COVID-19: Hidden figures in COVID-19 risk models
inferred← citeshttps://doi.org/10.1016/j.humimm.2021.02.007openalex-snapshot
Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes
inferred← citeshttps://doi.org/10.1016/j.ijantimicag.2020.106208openalex-snapshot
Therapeutic modalities and novel approaches in regenerative medicine for COVID-19
inferred← citeshttps://doi.org/10.1016/j.ijid.2020.10.074openalex-snapshot
The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
inferred← citeshttps://doi.org/10.1016/j.intimp.2020.107262openalex-snapshot
Convalescent plasma may be a possible treatment for COVID-19: A systematic review
inferred← citeshttps://doi.org/10.1016/j.intimp.2021.108232openalex-snapshot
SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies
inferred← citeshttps://doi.org/10.1016/j.jiph.2021.10.028openalex-snapshot
Efficacy and safety of convalescent plasma therapy in patients with moderate-to-severe COVID-19: A non-randomized comparative study with historical control in a referral hospital in Indonesia
inferred← citeshttps://doi.org/10.1016/j.mayocpiqo.2020.09.010openalex-snapshot
Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2
inferred← citeshttps://doi.org/10.1016/j.mayocpiqo.2021.03.007openalex-snapshot
Anti-Inflammatory Treatment of COVID-19 Pneumonia With Tofacitinib Alone or in Combination With Dexamethasone is Safe and Possibly Superior to Dexamethasone as a Single Agent in a Predominantly African American Cohort
inferred← citeshttps://doi.org/10.1016/j.tracli.2020.09.001openalex-snapshot
A case of COVID-19 Convalescent Plasma Donation in Greece: Directed donation for compassionate use in the donor's critically ill father
inferred← citeshttps://doi.org/10.1016/j.tracli.2021.02.003openalex-snapshot
Constraints and challenges in convalescent plasma collection amidst the Covid 19 pandemic- strategies and recommendations to overcome these
inferred← citeshttps://doi.org/10.1016/j.tracli.2021.04.009openalex-snapshot
Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions
inferred← citeshttps://doi.org/10.1016/j.transci.2020.102957openalex-snapshot
Promoting access to COVID-19 convalescent plasma in low- and middle-income countries
inferred← citeshttps://doi.org/10.1016/j.transci.2021.103063openalex-snapshot
A look-back at convalescent plasma to treat COVID-19
inferred← citeshttps://doi.org/10.1016/j.transci.2021.103075openalex-snapshot
Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies
inferred← citeshttps://doi.org/10.1016/j.transci.2021.103158openalex-snapshot
Efficacy of convalescent plasma therapy in severe COVID-19 patients
inferred← citeshttps://doi.org/10.1016/j.transci.2021.103321openalex-snapshot
Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19
inferred← citeshttps://doi.org/10.1016/j.transci.2022.103455openalex-snapshot
Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients
inferred← citeshttps://doi.org/10.1016/j.xcrm.2020.100164openalex-snapshot
Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency
inferred← citeshttps://doi.org/10.1016/j.ymthe.2020.10.004openalex-snapshot
Prepandemic Preparedness under the Spotlight at ASGCT’s COVID-19 Symposium
inferred← citeshttps://doi.org/10.1017/ice.2020.442openalex-snapshot
Whither immunity? The search for effective, durable immunity to coronavirus disease 2019 (COVID-19)
inferred← citeshttps://doi.org/10.1021/acs.analchem.1c03654openalex-snapshot
Quantitation of Trastuzumab and an Antibody to SARS-CoV-2 in Minutes Using Affinity Membranes in 96-Well Plates
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.0c00608openalex-snapshot
COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies
inferred← citeshttps://doi.org/10.1021/acsbiomaterials.0c01287openalex-snapshot
Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19
inferred← citeshttps://doi.org/10.1038/d41586-020-02324-2openalex-snapshot
Evidence lags behind excitement over blood plasma as a coronavirus treatment
inferred← citeshttps://doi.org/10.1038/s41415-020-2228-9openalex-snapshot
Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2
inferred← citeshttps://doi.org/10.1038/s41467-021-23469-2openalex-snapshot
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
inferred← citeshttps://doi.org/10.1038/s41467-022-28064-7openalex-snapshot
A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19
inferred← citeshttps://doi.org/10.1038/s41467-022-34728-1openalex-snapshot
Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19
inferred← citeshttps://doi.org/10.1038/s41577-021-00542-xopenalex-snapshot
Neutralizing monoclonal antibodies for treatment of COVID-19
inferred← citeshttps://doi.org/10.1038/s41586-020-03041-6openalex-snapshot
Correlates of protection against SARS-CoV-2 in rhesus macaques
inferred← citeshttps://doi.org/10.1038/s41598-021-87137-7openalex-snapshot
Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray
inferred← citeshttps://doi.org/10.1038/s41598-021-89444-5openalex-snapshot
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
inferred← citeshttps://doi.org/10.1038/s41598-021-99917-2openalex-snapshot
Visible blue light inhibits infection and replication of SARS-CoV-2 at doses that are well-tolerated by human respiratory tissue
inferred← citeshttps://doi.org/10.1038/s41598-024-75093-xopenalex-snapshot
Biochemical rationale for transfusion of high titre COVID-19 convalescent plasma
inferred← citeshttps://doi.org/10.1038/s42003-021-01813-yopenalex-snapshot
Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
inferred← citeshttps://doi.org/10.1056/nejmc2114591openalex-snapshot
Convalescent Plasma for Outpatients with Covid-19
inferred← citeshttps://doi.org/10.1056/nejmoa2029849openalex-snapshot
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
inferred← citeshttps://doi.org/10.1056/nejmoa2031304openalex-snapshot
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
inferred← citeshttps://doi.org/10.1056/nejmoa2033700openalex-snapshot
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
inferred← citeshttps://doi.org/10.1056/nejmoa2035002openalex-snapshot
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
inferred← citeshttps://doi.org/10.1056/nejmoa2102685openalex-snapshot
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
inferred← citeshttps://doi.org/10.1073/pnas.2020930117openalex-snapshot
The pandemic is prompting widespread use—and misuse—of real-world data
inferred← citeshttps://doi.org/10.1073/pnas.2414957121openalex-snapshot
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma
inferred← citeshttps://doi.org/10.1080/00207233.2020.1864185openalex-snapshot
Convalescent plasma therapy for coronavirus patients and the experience of Kurdistan Region of Iraq
inferred← citeshttps://doi.org/10.1080/08830185.2020.1840566openalex-snapshot
Pathogenesis Guided Therapeutic Management of COVID-19: An Immunological Perspective
inferred← citeshttps://doi.org/10.1080/08923973.2020.1863983openalex-snapshot
Different aspects of convalescent plasma therapy for COVID-19 treatment; a critical review
inferred← citeshttps://doi.org/10.1080/13543784.2021.1847270openalex-snapshot
An overview on the use of antivirals for the treatment of patients with COVID19 disease
inferred← citeshttps://doi.org/10.1080/15265161.2020.1820113openalex-snapshot
Response to Open Peer Commentary “Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs”
inferred← citeshttps://doi.org/10.1080/15265161.2021.1849503openalex-snapshot
Don’t Blame Hippocrates for Low Enrollment in Clinical Trials
inferred← citeshttps://doi.org/10.1080/17434440.2021.1915764openalex-snapshot
Mortality in mechanically ventilated patients with COVID-19: a systematic review
inferred← citeshttps://doi.org/10.1080/19420862.2021.1893426openalex-snapshot
Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2
inferred← citeshttps://doi.org/10.1080/20476965.2023.2237745openalex-snapshot
Beyond mathematics, statistics, and programming: data science, machine learning, and artificial intelligence competencies and curricula for clinicians, informaticians, science journalists, and researchers
inferred← citeshttps://doi.org/10.1080/23744235.2021.1940271openalex-snapshot
Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients – a safe but futile intervention. A comparative cohort study
inferred← citeshttps://doi.org/10.1080/23744235.2024.2329957openalex-snapshot
Double-blinded, randomised, placebo-controlled trial of convalescent plasma for COVID-19: analyses by neutralising antibodies homologous to recipients’ variants
inferred← citeshttps://doi.org/10.1080/26895293.2021.1977186openalex-snapshot
SARS-CoV-2 mechanisms of action and impact on human organism, risk factors and potential treatments. An exhaustive survey
inferred← citeshttps://doi.org/10.1093/cid/ciaa1548openalex-snapshot
Convalescent Plasma for Patients With Severe Coronavirus Disease 2019 (COVID-19): A Matched Cohort Study
inferred← citeshttps://doi.org/10.1093/cid/ciaa1583openalex-snapshot
Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab
inferred← citeshttps://doi.org/10.1093/cid/ciaa1653openalex-snapshot
US Food and Drug Administration (FDA) Emergency Use Authorization: Glass Half Full or Glass Half Empty?
inferred← citeshttps://doi.org/10.1093/cid/ciab317openalex-snapshot
Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients
inferred← citeshttps://doi.org/10.1093/cid/ciab880openalex-snapshot
Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords
inferred← citeshttps://doi.org/10.1093/cid/ciac724openalex-snapshot
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
inferred← citeshttps://doi.org/10.1093/femsre/fuab035openalex-snapshot
The Immunopathobiology of SARS-CoV-2 Infection
inferred← citeshttps://doi.org/10.1093/ilar/ilab010openalex-snapshot
Animal Models of COVID-19 II. Comparative Immunology
inferred← citeshttps://doi.org/10.1093/infdis/jiaa673openalex-snapshot
Neutralizing Antibody Responses in COVID-19 Convalescent Sera
inferred← citeshttps://doi.org/10.1093/infdis/jiaa803openalex-snapshot
Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma
inferred← citeshttps://doi.org/10.1093/jac/dkaa442openalex-snapshot
Treating COVID-19: are we missing out the window of opportunity?
inferred← citeshttps://doi.org/10.1093/labmed/lmac055openalex-snapshot
Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State
inferred← citeshttps://doi.org/10.1093/ofid/ofab176openalex-snapshot
Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
inferred← citeshttps://doi.org/10.1093/ofid/ofab335openalex-snapshot
Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report
inferred← citeshttps://doi.org/10.1093/ofid/ofab391openalex-snapshot
Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study
inferred← citeshttps://doi.org/10.1093/pnasnexus/pgac062openalex-snapshot
Abnormal antibodies to self-carbohydrates in SARS-CoV-2-infected patients
inferred← citeshttps://doi.org/10.1093/qjmed/hcaa341openalex-snapshot
Rapid recovery of taste and smell in a patient with SARS-CoV-2 following convalescent plasma therapy
inferred← citeshttps://doi.org/10.1097/aln.0000000000003608openalex-snapshot
Peer Review Matters: Research Quality and the Public Trust
inferred← citeshttps://doi.org/10.1097/ccm.0000000000005066openalex-snapshot
Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial*
inferred← citeshttps://doi.org/10.1097/id9.0000000000000033openalex-snapshot
Effectiveness and Controversy of Convalescent Plasma Therapy for Coronavirus Disease 2019 Patients
inferred← citeshttps://doi.org/10.1097/inf.0000000000003166openalex-snapshot
Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients
inferred← citeshttps://doi.org/10.1097/mcp.0000000000000766openalex-snapshot
Coronavirus disease 2019 management
inferred← citeshttps://doi.org/10.1097/mop.0000000000000983openalex-snapshot
Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics
inferred← citeshttps://doi.org/10.1097/mot.0000000000000888openalex-snapshot
The solid organ transplant recipient with SARS-CoV-2 infection
inferred← citeshttps://doi.org/10.1097/tp.0000000000003519openalex-snapshot
COVID-19 Therapeutics for Solid Organ Transplant Recipients; 6 Months Into the Pandemic: Where Are We Now?
inferred← citeshttps://doi.org/10.1097/tp.0000000000003523openalex-snapshot
COVID-19 and Solid Organ Transplantation: A Review Article
inferred← citeshttps://doi.org/10.1097/tp.0000000000003536openalex-snapshot
Solid Organ Transplantation in the Era of COVID-19: Lessons from France
inferred← citeshttps://doi.org/10.1101/2020.09.01.20184390openalex-snapshot
Convalescent plasma as potential therapy for severe COVID-19 pneumonia
inferred← citeshttps://doi.org/10.1101/2020.09.10.20191486openalex-snapshot
Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
inferred← citeshttps://doi.org/10.1101/2020.09.17.20195131openalex-snapshot
Seroprevalence of Antibodies to SARS-CoV-2 in US Blood Donors
inferred← citeshttps://doi.org/10.1101/2020.09.22.20192443openalex-snapshot
Reinfection with SARS-CoV-2 and Failure of Humoral Immunity: a case report
inferred← citeshttps://doi.org/10.1101/2020.10.08.20202606openalex-snapshot
EFFECT OF CONVALESCENT PLASMA ON MORTALITY IN PATIENTS WITH COVID-19 PNEUMONIA
inferred← citeshttps://doi.org/10.1101/2020.10.21.20216960openalex-snapshot
Emergency Response for Evaluating SARS-CoV-2 Immune Status, Seroprevalence and Convalescent Plasma in Argentina
inferred← citeshttps://doi.org/10.1101/2020.10.25.20219147openalex-snapshot
Fluctuating High Throughput Serological Assay Results in Recurrent Convalescent Plasma Donors
inferred← citeshttps://doi.org/10.1101/2020.11.08.20224790openalex-snapshot
Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency
inferred← citeshttps://doi.org/10.1101/2020.11.19.20234757openalex-snapshot
Mortality rates in matched cohort, pseudo-randomised and randomised trials of convalescent plasma given to COVID-19 patients
inferred← citeshttps://doi.org/10.1101/2020.11.30.20218560openalex-snapshot
Convalescent Plasma in COVID-19. Mortality-Safety First Results of the Prospective Multicenter FALP 001-2020 Trial
inferred← citeshttps://doi.org/10.1101/2020.12.31.424729openalex-snapshot
The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates
inferred← citeshttps://doi.org/10.1101/2021.02.08.21251348openalex-snapshot
Protocol for rapid implementation of a SARS-CoV-2 sero-survey during the 2020 COVID-19 pandemic – who, where, how?
inferred← citeshttps://doi.org/10.1101/2021.02.25.21252463openalex-snapshot
Donor Anti-Spike Immunity is Related to Recipient Recovery and Can Predict the Efficacy of Convalescent Plasma Units
inferred← citeshttps://doi.org/10.1101/2021.03.05.21251413openalex-snapshot
THE EFFECTIVENESS OF ACB-IP 1.0 UNIVERSAL PATHOGEN FREE CONCENTRATED COCKTAIL CONVALESCENT PLASMA IN COVID-19 INFECTION
inferred← citeshttps://doi.org/10.1101/2021.08.04.21261507openalex-snapshot
Durability and Cross-Reactivity of Immune Responses Induced by an AS03-Adjuvanted Plant-Based Recombinant Virus-Like Particle Vaccine for COVID-19
inferred← citeshttps://doi.org/10.1101/2021.09.14.460394openalex-snapshot
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection
inferred← citeshttps://doi.org/10.1101/2022.02.18.481058openalex-snapshot
Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains
inferred← citeshttps://doi.org/10.1111/bjh.17272openalex-snapshot
Early mortality benefit with COVID‐19 convalescent plasma: a matched control study
inferred← citeshttps://doi.org/10.1111/deci.70007openalex-snapshot
Medical countermeasures during public health emergencies—Does information sharing among health system coalition help?
inferred← citeshttps://doi.org/10.1111/petr.13986openalex-snapshot
SARS‐CoV‐2 and pediatric solid organ transplantation: Current knowns and unknowns
inferred← citeshttps://doi.org/10.1111/tme.12729openalex-snapshot
Safety and efficacy of COVID‐19 convalescent plasma in severe pulmonary disease: A report of 17 patients
inferred← citeshttps://doi.org/10.1111/tme.12745openalex-snapshot
The need for and challenges of comparing SARS‐CoV‐2 antibody assays
inferred← citeshttps://doi.org/10.1111/tme.12803openalex-snapshot
Systematic review and meta‐analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 ( COVID ‐19): Evidence‐base for practise and implications for research
inferred← citeshttps://doi.org/10.1111/trf.16177openalex-snapshot
Transfusion reactions associated with COVID ‐19 convalescent plasma therapy for SARS‐CoV ‐2
inferred← citeshttps://doi.org/10.1111/trf.16253openalex-snapshot
Screening donors for COVID ‐19 convalescent plasma
inferred← citeshttps://doi.org/10.1111/trf.16261openalex-snapshot
Presence and short‐term persistence of SARS‐CoV ‐2 neutralizing antibodies in COVID ‐19 convalescent plasma donors
inferred← citeshttps://doi.org/10.1111/trf.16278openalex-snapshot
The effect of COVID ‐19 on blood donation habits
inferred← citeshttps://doi.org/10.1111/trf.16286openalex-snapshot
COVID‐19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors
inferred← citeshttps://doi.org/10.1111/trf.16291openalex-snapshot
Longitudinal analysis of SARS‐CoV ‐2 antibodies in 8000 U.S. first‐time convalescent plasma donations
inferred← citeshttps://doi.org/10.1111/trf.16293openalex-snapshot
Impact of serological and PCR testing requirements on the selection of COVID ‐19 convalescent plasma donors
inferred← citeshttps://doi.org/10.1111/trf.16321openalex-snapshot
Selecting COVID ‐19 convalescent plasma for neutralizing antibody potency using a high‐capacity SARS‐CoV ‐2 antibody assay
inferred← citeshttps://doi.org/10.1111/trf.16435openalex-snapshot
Are We Forgetting About IgA? A Re‐examination of Coronavirus Disease 2019 Convalescent Plasma
inferred← citeshttps://doi.org/10.1111/trf.16525openalex-snapshot
Use of convalescent plasma in COVID ‐19 patients with immunosuppression
inferred← citeshttps://doi.org/10.1111/trf.16580openalex-snapshot
Assessment of serological assays for identifying high titer convalescent plasma
inferred← citeshttps://doi.org/10.1111/trf.16711openalex-snapshot
Active surveillance of serious adverse events following transfusion of COVID ‐19 convalescent plasma
inferred← citeshttps://doi.org/10.1111/trf.16751openalex-snapshot
Regulatory challenges of convalescent plasma collection during the evolving stages of COVID ‐19 pandemic in the United States
inferred← citeshttps://doi.org/10.1111/trf.17083openalex-snapshot
Characterization of pathogen‐inactivated COVID ‐19 convalescent plasma and responses in transfused patients
inferred← citeshttps://doi.org/10.1111/trf.17174openalex-snapshot
Comparison of allocation strategies of convalescent plasma to reduce excess infections and mortality from SARS‐CoV ‐2 in a US ‐like population
inferred← citeshttps://doi.org/10.1111/vox.13060openalex-snapshot
Evaluation of SARS‐CoV‐2 antibody titers and potency for convalescent plasma donation: a brief commentary
inferred← citeshttps://doi.org/10.1111/vox.13091openalex-snapshot
COVID‐19 convalescent plasma therapy: hit fast, hit hard!
inferred← citeshttps://doi.org/10.1111/vox.13114openalex-snapshot
International Forum on the Collection and Use of COVID‐19 Convalescent Plasma: Responses
inferred← citeshttps://doi.org/10.1111/vox.13162openalex-snapshot
Qualifying coronavirus disease 2019 convalescent plasma donors in Israel
inferred← citeshttps://doi.org/10.1111/vox.13228openalex-snapshot
COVID‐19 convalescent plasma: Evolving strategies for serological screening in France
inferred← citeshttps://doi.org/10.1111/vox.70140openalex-snapshot
Autoantibodies in COVID ‐19 convalescent plasma donors
inferred← citeshttps://doi.org/10.1111/voxs.12644openalex-snapshot
Correlation of sample‐to‐cut‐off ratio of anti‐SARS‐CoV‐2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multi‐centric study in India
inferred← citeshttps://doi.org/10.1126/sciadv.abe6855openalex-snapshot
Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
inferred← citeshttps://doi.org/10.1126/scitranslmed.abe0948openalex-snapshot
Prospects for a safe COVID-19 vaccine
inferred← citeshttps://doi.org/10.1128/cmr.00200-21openalex-snapshot
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
inferred← citeshttps://doi.org/10.1128/cmr.00249-25openalex-snapshot
IgY passive immunotherapy for pandemic preparedness: a One Health platform approach against pathogen X
inferred← citeshttps://doi.org/10.1128/jcm.02005-20openalex-snapshot
Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients
inferred← citeshttps://doi.org/10.1128/jcm.02257-20openalex-snapshot
Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers
inferred← citeshttps://doi.org/10.1128/mbio.00765-21openalex-snapshot
Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
inferred← citeshttps://doi.org/10.1128/spectrum.02560-21openalex-snapshot
Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile
inferred← citeshttps://doi.org/10.1136/bmj.m3327openalex-snapshot
Covid-19: US approves emergency use of convalescent plasma despite warnings over lack of evidence
inferred← citeshttps://doi.org/10.1136/bmj.m3373openalex-snapshot
Seven days in medicine: 26 Aug to 1 Sep 2020
inferred← citeshttps://doi.org/10.1136/bmj.m3939openalex-snapshot
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
inferred← citeshttps://doi.org/10.1136/bmj.n436openalex-snapshot
Severe covid-19 pneumonia: pathogenesis and clinical management
inferred← citeshttps://doi.org/10.1136/bmjopen-2021-055189openalex-snapshot
Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial)
inferred← citeshttps://doi.org/10.1136/bmjresp-2021-001017openalex-snapshot
Efficacy of convalescent plasma for treatment of COVID-19 in Uganda
inferred← citeshttps://doi.org/10.11603/1811-2471.2021.v.i1.11987openalex-snapshot
ПОСТКОВІДНИЙ СИНДРОМ: КЛІНІЧНІ ПРОЯВИ ТА ЇХ ОСОБЛИВОСТІ
showing the first 200 of 336 · page through all 336
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.